{"title":"네이버 금융 ─ 뉴스 ─ 기업 종목분석","url":"https://finance.naver.com/news/news_list.naver?mode=LSS3D&section_id=101&section_id2=258&section_id3=402","favicon":"https://finance.naver.com/news/favicon.ico","elements":[{"title":"[특징주] 씨앤투스성진, 200% 무상증자·자사주 소각 소식에 25% 급등","contents":"<a href=\"/news/news_read.naver?article_id=0003989409&amp;office_id=011&amp;mode=LSS3D&amp;type=0&amp;section_id=101&amp;section_id2=258&amp;section_id3=402&amp;date=20211125&amp;page=1\" title=\"[특징주] 씨앤투스성진, 200% 무상증자·자사주 소각 소식에 25% 급등\">[특징주] 씨앤투스성진, 200% 무상증자·자사주 소각 소식에 25% 급등</a>","link":"https://finance.naver.com/news/news_read.naver?article_id=0003989409&office_id=011&mode=LSS3D&type=0&section_id=101&section_id2=258&section_id3=402&date=20211125&page=1","retrieved":1637804977287},{"title":"'라라랜드' 품은 CJ ENM…물적분할의 악몽","contents":"<a href=\"/news/news_read.naver?article_id=0005005281&amp;office_id=277&amp;mode=LSS3D&amp;type=0&amp;section_id=101&amp;section_id2=258&amp;section_id3=402&amp;date=20211125&amp;page=1\" title=\"'라라랜드' 품은 CJ ENM…물적분할의 악몽\">'라라랜드' 품은 CJ ENM…물적분할의 악몽</a>","link":"https://finance.naver.com/news/news_read.naver?article_id=0005005281&office_id=277&mode=LSS3D&type=0&section_id=101&section_id2=258&section_id3=402&date=20211125&page=1","retrieved":1637804977288},{"title":"[특징주] 식지 않는 메타버스 열기...AR·VR 기술주 강세","contents":"<a href=\"/news/news_read.naver?article_id=0003989391&amp;office_id=011&amp;mode=LSS3D&amp;type=0&amp;section_id=101&amp;section_id2=258&amp;section_id3=402&amp;date=20211125&amp;page=1\" title=\"[특징주] 식지 않는 메타버스 열기...AR·VR 기술주 강세\">[특징주] 식지 않는 메타버스 열기...AR·VR 기술주 강세</a>","link":"https://finance.naver.com/news/news_read.naver?article_id=0003989391&office_id=011&mode=LSS3D&type=0&section_id=101&section_id2=258&section_id3=402&date=20211125&page=1","retrieved":1637804977289},{"title":"툴젠 \"유전자교정 플랫폼 ·유전자·세포치료제 글로벌 선도 기업 도약\"","contents":"<a href=\"/news/news_read.naver?article_id=0004632722&amp;office_id=015&amp;mode=LSS3D&amp;type=0&amp;section_id=101&amp;section_id2=258&amp;section_id3=402&amp;date=20211125&amp;page=1\" title=\"툴젠 &quot;유전자교정 플랫폼 ·유전자·세포치료제 글로벌 선도 기업 도약&quot;\">툴젠 \"유전자교정 플랫폼 ·유전자·세포치료제 글로벌 선도 기업 도약\"</a>","link":"https://finance.naver.com/news/news_read.naver?article_id=0004632722&office_id=015&mode=LSS3D&type=0&section_id=101&section_id2=258&section_id3=402&date=20211125&page=1","retrieved":1637804977291},{"title":"드래곤플라이·펄어비스·엔씨소프트…게임株, NFT 규제뚫고 고공비행","contents":"<a href=\"/news/news_read.naver?article_id=0004675067&amp;office_id=008&amp;mode=LSS3D&amp;type=0&amp;section_id=101&amp;section_id2=258&amp;section_id3=402&amp;date=20211125&amp;page=1\" title=\"드래곤플라이·펄어비스·엔씨소프트…게임株, NFT 규제뚫고 고공비행\">드래곤플라이·펄어비스·엔씨소프트…게임株, NFT 규제뚫고 고공비행</a>","link":"https://finance.naver.com/news/news_read.naver?article_id=0004675067&office_id=008&mode=LSS3D&type=0&section_id=101&section_id2=258&section_id3=402&date=20211125&page=1","retrieved":1637804977291},{"title":"컴투스, 교보문고·위지윅과 메타버스 사업 협력 MOU","contents":"<a href=\"/news/news_read.naver?article_id=0004884147&amp;office_id=009&amp;mode=LSS3D&amp;type=0&amp;section_id=101&amp;section_id2=258&amp;section_id3=402&amp;date=20211125&amp;page=1\" title=\"컴투스, 교보문고·위지윅과 메타버스 사업 협력 MOU\">컴투스, 교보문고·위지윅과 메타버스 사업 협력 MOU</a>","link":"https://finance.naver.com/news/news_read.naver?article_id=0004884147&office_id=009&mode=LSS3D&type=0&section_id=101&section_id2=258&section_id3=402&date=20211125&page=1","retrieved":1637804977292},{"title":"루닛, 북미영상의학회서 흉부CT·유방단층촬영 AI 신제품 공개","contents":"<a href=\"/news/news_read.naver?article_id=0004632715&amp;office_id=015&amp;mode=LSS3D&amp;type=0&amp;section_id=101&amp;section_id2=258&amp;section_id3=402&amp;date=20211125&amp;page=1\" title=\"루닛, 북미영상의학회서 흉부CT·유방단층촬영 AI 신제품 공개\">루닛, 북미영상의학회서 흉부CT·유방단층촬영 AI 신제품 공개</a>","link":"https://finance.naver.com/news/news_read.naver?article_id=0004632715&office_id=015&mode=LSS3D&type=0&section_id=101&section_id2=258&section_id3=402&date=20211125&page=1","retrieved":1637804977293}]}